tradingkey.logo
tradingkey.logo
Buscar

Eli Lilly and Co

LLY
Añadir a la lista de seguimiento
1208.120USD
+79.000+7.01%
Cierre 06/26, 16:00ETCotizaciones retrasadas 15 min
1.14TCap. mercado
42.84P/E TTM

Más Datos de Eli Lilly and Co Compañía

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).

Información de Eli Lilly and Co

Símbolo de cotizaciónLLY
Nombre de la empresaEli Lilly and Co
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)
Número de empleados47000
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 09
DirecciónLilly Corporate Ctr
CiudadINDIANAPOLIS
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal46285
Teléfono13172762000
Sitio Webhttps://www.lilly.com/
Símbolo de cotizaciónLLY
Fecha de salida a bolsaJul 09, 1970
Director ejecutivoRicks (David A)

Ejecutivos de Eli Lilly and Co

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.54K
+0.70%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
16.26K
+9.66%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
14.46K
+31.93%
Ms. Kimberly H. Johnson
Ms. Kimberly H. Johnson
Independent Director
Independent Director
3.27K
+0.67%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Eli Lilly and Co?

Los cinco principales accionistas de Eli Lilly and Co son: Ms. Anne E. White

¿Cuántas instituciones poseen acciones de Eli Lilly and Co (LLY)?

A fecha de 2026Q1, 6331 instituciones poseen acciones de Eli Lilly and Co, con un valor de mercado combinado de aproximadamente 864.16M, lo que representa el 91.72% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 69007266.00.

¿Cuál es la mayor fuente de ganancias de Eli Lilly and Co?

El 2026Q1, el segmento empresarial Diabetes-Mounjaro generó la ganancia más alta para Eli Lilly and Co, ascendiendo a 6.52B y representando el 37.02% de la ganancia total.
KeyAI